颈管细胞及化生细胞在宫颈液基细胞学检查中的临床价值被引量：2

Clinical Value of Endocervical Cells and Metaplastic Cells by Liquid-based Cytology Technique

导出

摘要目的探讨颈管细胞(EC)和化生细胞(MSC)在宫颈病变筛查中的临床价值。方法将28 952份液基细胞学标本按颈管细胞和化生细胞存在状态分为EC(+)/MSC(+)、EC(+)or MSC(+)及EC(-)/MSC(-)等3组,比较各组液基标本的满意率和细胞学异常的检出率。结果细胞学异常总检出率为3.54%,其中低级别上皮内瘤变(LSIL)、高级别上皮内瘤变(HSIL)及宫颈鳞癌(SCC)检出率分别为1.11%、0.36%、0.02%;细胞学异常总检出率在EC(+)/MSC(+)组最高(7.82%),其次是EC(+)or MSC(+)组(5.21%),EC(-)/MSC(-)组检出率最低(1.28%),差异具有统计学意义(P<0.01)。EC(+)/MSC(+)组液基标本满意率(细胞量>40%)达89.77%,EC(+)or MSC(+)组次之(77.67%),EC(-)/MSC(-)组为70.42%,差异有统计学意义(P<0.01)。结论液基细胞学检查标本中颈管细胞及化生细胞存在与否对液基标本质量和宫颈细胞学异常的总检出率有影响。 Objective To investigate the clinical significance of endocervical cells（EC）and metaplastic squamous cells（MSC）in the screening of cervical cancer.Methods The screening results and the status of EC and MSC of 28 952 copies were statistically calculated to compare the satisfaction rate and the detection rate of abnormal cytology under different cellular components.Results The overall detection rate of abnormal cytology was 3.54%,and the coincidence rate of LSIL,HISL and SCC was 1.11%,0.36% and 0.02%,respectively.The detection rate was highest in EC（＋）/MSC（＋）group（7.82%）,followed by EC（＋）or MSC（＋）group（5.21%）,and the lowest detection rate（1.28%）was found in EC（-）/MSC（-）group（P0.01）.The satisfaction rate was highest in EC（＋）/MSC（＋）group（89.77%）,followed by EC（＋）or MSC（＋）group（77.67%）and EC（-）/MSC（-）group（70.42%）（P0.01）.Conclusion The status of EC and MSC affects the overall detection rate of abnormal cervical cytology.

作者陈枝岚黄科程胡婷杨茹李雄张庆华贾瑶沈健王少帅唐方徐周航马丁王世宣李双

机构地区华中科技大学同济医学院附属同济医院妇科肿瘤实验室广州军区武汉总医院妇产科武汉市中心医院妇产科

出处《华中科技大学学报（医学版）》 CAS CSCD 北大核心 2012年第3期320-323,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基金国家重点基础发展计划("973"计划)(No.2009CB521808) 卫生公益性行业科研专项基金(No.201002013) 国家自然科学基金(No.81101964 30973472 81001151 81071663 30973205 30973184)资助项目

关键词液基薄层细胞学颈管细胞化生细胞 liquid-based cytology technique endocervical cells metaplastic squamous cells

分类号 R446.82 [医药卫生—诊断学]

引文网络
相关文献

参考文献2

1沈怡,王泽华.Total Laparoscopic Radical Hysterectomy for Treatment of Uterine Malignant Tumors:Analysis of Short-term Therapeutic Efficacy[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(3):375-378. 被引量：4
2黄斌,李瑞珍,吴瑞芳,汤惠茹,刘志红,乌兰娜,李鹃,王纯,周艳秋,翁雷明.HPV L1壳蛋白与hTERC基因检测及联合分析对宫颈癌筛查的意义[J].华中科技大学学报（医学版）,2010,39(4):554-557. 被引量：25

二级参考文献14

1Dehn D,Torkko K C,Shroyer R.Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma[J].Cancer,2007,111(1):1-14.
2Yoshida T,Sano T,Kanuma T,et al.Immunochemical analysis of HPV L1 capisid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions[J].Cancer,2008,114(2):83-88.
3Arafa M,Boniver J,Delvenne P.Detection of HPV-induced cervical(pre)neoplastic lesions.A tissue microarry(TMA)study[J].Appl Immunohistochem Mol Morphol,2008,16(5):422-432.
4Hilfrich R,Hariri J.Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker[J].Anal Quant Cytol Histol,2008,30(2):78-82.
5Hopman A H,Theelen W,Hommelberg P P,et al.Genomic intergration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer[J].J Pathol,2006,210(4):412-419.
6Melsheimer P,Kaul S,Dobeck S,et al.Immunocytochemical detection of human papillomavirus high risk type L1 capsid protein in LSIL and HSIL as compared with detection of HPV L1 DNA[J].Acta Cytol,2003,47(2):124-128.
7Stanley M.Immune response to human papillomavirus[J].Vaccine,2006,24(Suppl.1):s16-22.
8Griesser H,Sander H,Hilfrich R,et al.Correlation of immunochemical detection of HPV L1 capsid protein in Pap smears with regression of High-risk HPV positive mild/moderate dysplasia[J].Anal Qytol Histl,2004,26(5):241-245.
9McMurry H R,Nguyen D,Westbrook T F,et al.Biology of human papillomaviruses[J].Int J Exp Path,2001,82(1):15-33.
10Hagensee M E,Koutsky L A,Lee S K,et al.Detection of cervical antibodies to human papillomavirus type 16(HPV-16)capsid antigens in relation to detection of HPV-16 DNA and cervical lesions[J].J Infect Dis,2000,181(4):1234-1239.